LRRC8A/VRAC离子通道抗肿瘤作用的研究进展  

Research progress on anti-tumor effects of LRRC8A volume-regulated anion channels

作　　者：杨润泽 胡耀华 秦靖 汪永锋 师长宏 YANG Runze;HU Yaohua;QIN Jing;WANG Yongfeng;SHI Changhong(Basic Medical College of Gansu University of Chinese Medicine,Lanzhou 730000,China.2.Medical College of Yan’an University,Yan’an 716000.3.Experimental Animal Center of Air Force Military Medical University,Xi’an 710000)

机构地区：[1]甘肃中医药大学基础医学院,兰州730000 [2]延安大学医学院,延安716000 [3]空军军医大学实验动物中心,西安710000

出　　处：《中国比较医学杂志》2024年第11期91-99,共9页Chinese Journal of Comparative Medicine

基　　金：国家自然科学基金(82160871);甘肃省自然科学基金资助项目(22JR5RA591);甘肃省中医药管理局项目(GZKZ-2021-10)。

摘　　要：体积调节阴离子通道(volume-regulated anion channels,VRAC)在脊椎动物细胞和各类型的肿瘤细胞中普遍表达。其由富含亮氨酸重复序列8A(leucine-rich repeat containing 8A,LRRC8A)及其4个同源家族成员(LRRC8B-E)组成,其中LRRC8A为必需亚基。已证实LRRC8A/VRAC通过各种信号途径参与肿瘤细胞的增殖、迁移、侵袭及多药耐药,并调控免疫细胞功能。该离子转运蛋白在杀伤肿瘤细胞及预防肿瘤中显示出良好的应用潜力,可作为肿瘤治疗的新靶点。本文综述了LRRC8A/VRAC参与肿瘤发生发展的最新研究,包括LRRC8A/VRAC的分子结构、功能及其在肿瘤中的调控作用,重点总结了LRRC8A/VRAC在肿瘤诊断和免疫治疗中的应用,以期为探索LRRC8A/VRAC成为肿瘤治疗的新靶点提供借鉴。Volume-regulated anion channels(VRACs)are present in vertebrate cells and a variety of tumor cells.VRACs include leucine-rich-repeat-containing 8A(LRRC8A)and its four homologous family members(LRRC8B-E),of which LRRC8A is an essential subunit.It has been confirmed that the VRAC LRRC8A is involved in the proliferation,migration,invasion,and multi-drug resistance of tumor cells through various signaling pathways.This ion transporter has shown good potential for use in strategies to kill tumor cells and prevent the development of tumors and can be used as a new target for tumor therapy.Therefore,this paper reviews the latest research on the involvement of LRRC8A in tumorigenesis and development.The molecular structure,function,and regulation of LRRC8A in tumor and immune cells,with emphasis on targeting LRRC8A in tumor diagnosis and immunotherapy,are discussed,providing a reference for studies exploring LRRC8A as a new tumor therapy target.

关 键 词：体积调节阴离子通道 富含亮氨酸重复序列8A 增殖 迁移 侵袭 多药耐药 肿瘤免疫 

分 类 号：R-33[医药卫生]